{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:07:27Z","timestamp":1792789647894,"version":"4.5.0"},"reference-count":49,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T00:00:00Z","timestamp":1698537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institutional Review Board (or Ethics Committee) of Citt\u00e0 della Salute e Della Scienza di Torino","award":["0005222"],"award-info":[{"award-number":["0005222"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: GP2017 is one of the biosimilar drugs of adalimumab, one of the anti-TNF agents used for inflammatory bowel disease (IBD). To date, there is little real-world data about the use of GP2017 in IBD patients. The aim of our study was to evaluate the effectiveness and safety of this biosimilar in an IBD population. (2) Methods: This is an observational retrospective study including patients that were all treated with GP2017 as a first step or as a switch from the originator or other biosimilars. The clinical activity was evaluated at baseline and after 6 and 12 months of therapy. The therapy discontinuation and side effects were also evaluated. (3) Results: a total of 72 patients were included (65 with Crohn\u2019s disease and 7 with ulcerative colitis). Of the 29 patients starting GP2017 as a first adalimumab therapy, clinical remission was achieved in 58.6%. Of the patients starting GP2017 as a switch from the originator (33 patients) or other biosimilars (10 patients), clinical remission was maintained in 78.8% and in 70%, respectively. Regarding the safety, only 11 patients experienced non-serious side effects. During the follow-up, nine patients suspended treatment mainly due to side effects or secondary failure. (4) Conclusions: GP2017 is an effective and safe therapy for IBD patients.<\/jats:p>","DOI":"10.3390\/jcm12216839","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T13:20:07Z","timestamp":1698672007000},"page":"6839","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-7638","authenticated-orcid":false,"given":"Marta","family":"Vernero","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10100 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0076-8549","authenticated-orcid":false,"given":"Cristina","family":"Bezzio","sequence":"additional","affiliation":[{"name":"IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"},{"name":"IBD Centre, IRCCS Humanitas, Research Hospital, 20089 Rozzano, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, 20072 Pieve Emanuele, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3087","authenticated-orcid":false,"given":"Davide G.","family":"Ribaldone","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10100 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7141-6551","authenticated-orcid":false,"given":"Stefania","family":"Costa","sequence":"additional","affiliation":[{"name":"Gastroenterology and Digestive Endoscopy Unit, Legnano Hospital, ASST Ovest Milanese, 20025 Legnano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7051-5432","authenticated-orcid":false,"given":"Davide","family":"Scalvini","sequence":"additional","affiliation":[{"name":"IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tribocco","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Turin, 10100 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpiero","family":"Manes","sequence":"additional","affiliation":[{"name":"IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-2534","authenticated-orcid":false,"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[{"name":"IBD Centre, Gastroenterology Unit, Rho Hospital, ASST Rhodense, 20017 Rho, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/flgastro-2018-101054","article-title":"Recent advances in monoclonal antibody therapy in IBD: Practical issues","volume":"10","author":"Tamilarasan","year":"2019","journal-title":"Frontline Gastroenterol."},{"key":"ref_3","unstructured":"Ellis, C.R., and Azmat, C.E. (2023, October 10). Adalimumab, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557889\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/bcp.15101","article-title":"Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review","volume":"88","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1517\/14740338.4.4.637","article-title":"Adalimumab: A review of side effects","volume":"4","author":"Scheinfeld","year":"2005","journal-title":"Expert Opin Drug Saf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: The CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: The CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1097\/MIB.0b013e318281f2b7","article-title":"52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and\/or immunosuppressants","volume":"19","author":"Reinisch","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/gut.2010.221127","article-title":"Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial","volume":"60","author":"Reinisch","year":"2011","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40001-022-00817-6","article-title":"Adalimumab for induction of remission in patients with Crohn\u2019s disease: A systematic review and meta-analysis","volume":"27","author":"Yin","year":"2022","journal-title":"Eur. J. Med. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2468-1253(21)00142-4","article-title":"Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): A randomised, controlled, phase 3 study","volume":"6","author":"Croft","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.4321\/S1130-01082011000600003","article-title":"Efficacy of adalimumab in patients with Crohn\u2019s disease and failure to infliximab therapy: A clinical series","volume":"103","year":"2011","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/gutjnl-2011-300755","article-title":"Switch to adalimumab in patients with Crohn\u2019s disease controlled by maintenance infliximab: Prospective randomised SWITCH trial","volume":"61","author":"Vermeire","year":"2012","journal-title":"Gut"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4321\/S1130-01082012000900004","article-title":"Efficacy of adalimumab for the treatment of extraintestinal manifestations of Crohn\u2019s disease","volume":"104","author":"Lorenzo","year":"2012","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/ecco-jcc\/jjx051","article-title":"Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn\u2019s Disease Recurrence. A GETECCU Randomised Trial","volume":"11","author":"Taxonera","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MEG.0b013e328353a32a","article-title":"Prevention of postoperative recurrence of Crohn\u2019s disease by Adalimumab: A case series","volume":"24","author":"Savarino","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gut.2008.159251","article-title":"Adalimumab for the treatment of fistulas in patients with Crohn\u2019s disease","volume":"58","author":"Colombel","year":"2009","journal-title":"Gut"},{"key":"ref_19","first-page":"442","article-title":"Use of biologics for the management of Crohn\u2019s disease: IG-IBD clinical guidelines based on the GRADE methodology","volume":"55","author":"Macaluso","year":"2023","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_20","first-page":"440","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_23","first-page":"632","article-title":"Use of biosimilars in inflammatory bowel disease: A position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","volume":"51","author":"Fiorino","year":"2019","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_24","unstructured":"(2023, August 29). Guideline on Similar Biological Medicinal Products. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-first-version_en.pdf."},{"key":"ref_25","first-page":"635","article-title":"GP2017: An Adalimumab Biosimilar","volume":"32","author":"Ya","year":"2018","journal-title":"BioDrugs Clin. Immunother. Biopharm. Gene Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjd.16890","article-title":"Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: Impact of multiple switches","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ribaldone, D.G., Tribocco, E., Rosso, C., Armandi, A., Vernero, M., Bugianesi, E., Astegiano, M., Saracco, G.M., and Caviglia, G.P. (2021). Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn\u2019s Disease: A Prospective Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153387"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"917814","DOI":"10.3389\/fphar.2022.917814","article-title":"Switching Among Biosimilars: A Review of Clinical Evidence","volume":"13","author":"Allocati","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohns Colitis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"Silverberg","year":"2005","journal-title":"Can. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15374","DOI":"10.3748\/wjg.v20.i41.15374","article-title":"Performance of the Montreal classification for inflammatory bowel diseases","volume":"20","author":"Spekhorst","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mocci, G., Bodini, G., Allegretta, L., Cazzato, A.I., Chiri, S., Aragona, G., Perazzo, P., Ferronato, A., Graziani, M.G., and Pagnini, C. (2022). Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081799"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/ibd\/izac092","article-title":"Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study","volume":"29","author":"Tursi","year":"2023","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wasserbauer, M., Hlava, S., Drabek, J., Stovicek, J., Minarikova, P., Nedbalova, L., Drasar, T., Zadorova, Z., Dolina, J., and Konecny, S. (2022). Adalimumab biosimilars in the therapy of Crohn\u2019s disease and ulcerative colitis: Prospective multicentric clinical monitoring. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0271299"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"411","DOI":"10.15403\/jgld-4608","article-title":"Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy","volume":"31","author":"Tursi","year":"2022","journal-title":"J. Gastrointest. Liver. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: Managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","article-title":"25 years of anti-TNF treatment for inflammatory bowel disease: Lessons from the past and a look to the future","volume":"70","year":"2021","journal-title":"Gut"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00296-019-04416-3","article-title":"Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: The FEARLESS cohort","volume":"40","author":"Favalli","year":"2020","journal-title":"Rheumatol. Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10620-018-5329-4","article-title":"Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy","volume":"64","author":"Sartini","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3899\/jrheum.151006","article-title":"Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study","volume":"43","author":"Hattori","year":"2016","journal-title":"J. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"989514","DOI":"10.3389\/fmed.2022.989514","article-title":"Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study","volume":"9","author":"Larid","year":"2022","journal-title":"Front. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"otab011","DOI":"10.1093\/crocol\/otab011","article-title":"Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis","volume":"3","author":"Mahlich","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ibd\/izaa152","article-title":"Cigarette Smoking, Coffee Consumption, Alcohol Intake, and Risk of Crohn\u2019s Disease and Ulcerative Colitis: A Mendelian Randomization Study","volume":"27","author":"Georgiou","year":"2021","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/ajg.2011.60","article-title":"Loss of response and need for adalimumab dose intensification in Crohn\u2019s disease: A systematic review","volume":"106","author":"Billioud","year":"2011","journal-title":"Am. J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00535-016-1274-1","article-title":"Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: Comparison between anti-tumour necrosis factor-na\u00efve and non-na\u00efve patients","volume":"52","author":"Iborra","year":"2017","journal-title":"J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000365783","article-title":"Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn\u2019s disease","volume":"90","author":"Miyoshi","year":"2014","journal-title":"Digestion"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.5114\/aoms.2016.58682","article-title":"An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis","volume":"12","author":"Kawalec","year":"2016","journal-title":"Arch. Med. Sci. AMS"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6839\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:13:55Z","timestamp":1760130835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/21\/6839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,29]]},"references-count":49,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2023,11]]}},"alternative-id":["jcm12216839"],"URL":"https:\/\/doi.org\/10.3390\/jcm12216839","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,29]]}}}